Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

OSI Pharmaceuticals updates anticancer programs

Nov. 13, 1998

Favorable phase III trial results presented for Evacet at ESMO; company prepares NDA

Nov. 12, 1998

Small-molecule FGFR-1 tyrosine kinase inhibitor with nanomolar potency and good selectivity

Nov. 12, 1998

Protein tyrosine kinase inhibitors for cancer, polycystic kidney disease

Nov. 12, 1998

New anticancer drug candidate revealed by Sugen; product enters phase I testing in U.K.

Nov. 11, 1998

Promising interim results announced for SU-5416 phase I trial

Nov. 10, 1998

Two major clinical studies demonstrate chemo- and radioprotective activity of amifostine

Nov. 10, 1998

Ribozyme initiates phase I clinical trials of Angiozyme

Nov. 9, 1998

GBC-590 effective in murine model of treatment-resistant pancreatic cancer

Nov. 9, 1998

Progen commences phase I trials of PI-88 in the U.K.

Nov. 6, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.